Search This Blog

Thursday, September 5, 2024

Anthrax kills Wyoming moose, more than 50 cattle, for first time in decades

 One moose and more than 50 cattle have died of anthrax in the past month in south-central Wyoming, officials confirmed Wednesday. 

Anthrax occurs naturally in soil but has not been documented in Wyoming in livestock since the 1970s and in wildlife since 1956. No humans have been infected, according to the Wyoming Department of Health.

Wildlife and veterinary health officials ask that anyone in Carbon County who encounters a dead animal such as elk, moose, deer, antelope or cattle with no obvious injury to leave it alone and call health officials.  

“For cattle, the main concern is for producers located within that region,” said Dr. Hallie Hasel, Wyoming’s state veterinarian. Cattle deaths can be a “serious economic loss” for ranchers, but Hasel notes veterinarians can order an effective vaccine that can be given annually for any cattle in at-risk areas to help curb the losses.

Cattle are omnipresent in the Laramie Mountains, seasonally grazing private pastureland along the range’s lower-elevation fringes and higher-elevation federal grazing allotments in summer. This inquisitive black cow strayed from its herd on April 19, 2022 south of Glenrock. (Mike Koshmrl/WyoFile)

Even though anthrax has not been documented in Wyoming in more than half a century, outbreaks do occur in livestock in places like Texas, the Dakotas and western Canada, said Dr. Samantha Allen, the state’s wildlife veterinarian. The bacteria can also live in soil for decades.

Wildlife and livestock officials don’t know exactly why the spore-forming bacterium, Bacillus anthracis, began killing cattle in the Elk Mountain region, but they said drought followed by heavy rain can sometimes trigger an outbreak. 

“While anthrax can sometimes be a human health concern, we have no worries at this time about a risk to the general public in Wyoming,” said Kim Deti, a spokesperson for the health department. “People can get sick with anthrax if they come in close contact with infected animals or contaminated animal products. Anthrax does not spread person to person.”

Cattle die off

Once infected with anthrax, animals will become lethargic, struggle to breathe and die within a couple of days, though some may succumb within 24 hours. An animal that has died of anthrax will often bleed through its nose, mouth or anus, will not have rigor mortis and will bloat quickly, Allen said. 

Cattle began dying of anthrax in the Elk Mountain area about a month ago, Hasel said, and health officials are aware of about 50 to 60 that have died so far across multiple cattle producers. The Wyoming State Veterinary Laboratory officially diagnosed the cattle with anthrax on Saturday. On Tuesday, the state lab confirmed that a moose found dead in the area also had anthrax. 

Elk Mountain is photographed from the west. (Mike Koshmrl/WyoFile)

Cattle and wildlife contract the disease by eating close to the soil in recently disturbed areas, Allen said. They can also contract it by nuzzling a dead carcass. Carnivores and scavengers like coyotes or lions are not generally as susceptible to the disease. It has historically been found in cattle in Laramie, Niobrara, Natrona, Carbon, Lincoln, Sublette and Teton counties. The last documented wild animal in Wyoming to die of anthrax was a moose in 1956 in Sublette County.

While anthrax sparks fears of the bioterrorism agent mailed to postal workers, journalists and government officials shortly after the Sept. 11, 2001 attacks, it is not exactly the same threat, she added. The powder sent in envelopes through the mail was a refined version of what lives naturally in soil. 

Before the 2001 attacks, people most likely to be infected with anthrax were ones who worked with animal hides, hair, bone and wool, according to the health department. Human cases are rare, but health officials still ask hunters and livestock producers to be cautious. 

Health precautions

Anyone hunting in the Elk Mountain area, where large elk herds range widely along with mule deer and pronghorn, should not shoot an animal that looks sick or touch a dead animal, Allen said.

The Game and Fish Department is not discouraging people from hunting in the Elk Mountain area as seasons begin, but instructed anyone in the area not to open an animal carcass “as this can lead to exposure to anthrax spores through the skin or inhalation,” according to a Game and Fish fact sheet. People should also not shoot a sick animal for the same reasons, or allow dogs, horses or other domestic animals to touch a carcass.

Neutrophil engulfing anthrax bacteria, taken with a Leo 1550 scanning electron microscope. Scale bar is 5 micrometers.(Volker Brinkmann, CC BY 2.5, via Wikimedia Commons)

Allen also recommends using disposable gloves and eye protection like sunglasses while field dressing wildlife. 

As for the dirt where the anthrax bacteria lives, Hasel said a change in weather “impacts the presence of bacteria in the soil.” Until then, cattle producers are asked to remove livestock from areas like irrigated hay meadows where cattle have become sick. The bacteria could resurface again next year, or years after that, but producers can work with their veterinarians to vaccinate cattle in the area.

Wildlife, livestock and health officials are also hosting a town hall meeting at 7 p.m. tonight in the Elk Mountain Fire Hall. 

The health department has also been working with people in high-exposure areas to get them preventative treatment such as antibiotics and vaccines, Deti said. 

“We’re asking all producers in that region if they have any acute deaths, do not move them or open them,” Hasel said. “Contact their veterinarian immediately.”

https://wyofile.com/anthrax-kills-wyoming-moose-for-first-time-in-decades-more-than-50-cattle/

Quidel upped to Buy from Hold by Craig Hallum

 Target to $57 from $40

https://finviz.com/quote.ashx?t=QDEL&ty=c&ta=1&p=d

Abbott Launches First-Ever Glucose Monitor For Non-Diabetics

 Abbott Laboratories (ABT) launched its newest continuous glucose monitor in the U.S. on Thursday. The biosensor named Lingo is the first-ever targeted for people without diabetes.

The move follows the launch of Dexcom's (DXCM) newest CGM, Stelo, last week. Stelo is targeted to people with prediabetes and type 2 diabetes who don't use insulin. But it's available over the counter, so people without diabetes will undoubtedly use it.

Olivier Ropars, divisional vice president of Abbott's Lingo business, says the company's move into metabolic health tracking is "genuinely transformative." Body-worn continuous glucose monitors, or CGMs, have long been a mainstay in tracking glucose for people with diabetes. But Lingo is for non-diabetics.

"It means a revolution in health overall," Ropars told Investor's Business Daily. "A strong decline in chronic disease over time. A better allocation of resources in the health care system. What we're talking about here is by giving these tools to the general population. We are finally investing in true health care — caring and managing health, not sick care."

https://www.investors.com/news/technology/abbott-laboratories-lingo-cgm-metabolic-health/

Zimmer Biomet Hammered, Sales Expected To Take A Surprise 1% Hit

 Zimmer Biomet (ZBH) stock tumbled Thursday after the medtech company said implementing a new enterprise system would slug 2024 sales by 1%.

The Warsaw, Ind.-based company, which sells hip and knee replacements, is planning to implement an enterprise resources planning system. As a result, full-year sales and earnings will take a hit, Evercore ISI analyst Vijay Kumar said in a report.

"While it is intended to gradually get better throughout the year, more than half of the impact is in the third quarter," Kumar said. "Additionally, this will impact EPS (which the company is looking to mitigate) and geographically will primarily impact the U.S. and Canada."

https://www.investors.com/news/technology/zimmer-biomet-stock-erp-implementation/

Moderna’s mpox vaccine prevents severe symptoms in monkeys, vs. Bavarian Nordic’s

 A new type of mpox, clade Ib, has been spreading rapidly within the Democratic Republic of Congo and leaking outside the African nation’s borders since Sept. 2023. In response, the World Health Organization (WHO) declared the outbreak a public health emergency of international concern (PHEIC) last month, the second such declaration for an mpox variant in the past two years.

The rise of mpox has sparked a mad dash to develop new vaccines that are safer, more effective and easier to manufacture. Moderna, a biotech best known for its mRNA Covid-19 vaccine, has aimed its expertise in the messenger molecules at mpox.

In a new study, Moderna’s mRNA vaccine candidate beat the dominant Jynneos vaccine at preventing severe disease and reducing virus levels in monkeys. The results were published in the journal Cell on Sept. 4.

“The mRNA-1769 vaccine appears promising,” Jean Nachega, M.D., Ph.D., an epidemiologist at the University of Pittsburgh who was not involved with the study, told Fierce Biotech in an email. “The vaccine's ability to elicit a strong immune response, combining neutralizing and functional antibodies, suggests its potential as an effective tool against mpox.”

Moderna first saw the need and opportunity for a new mpox vaccine after the first PHEIC was declared in 2022, Alec Freyn, Ph.D., principal scientist in the biotech’s virology group, told Fierce in an interview.

“We started to advance preclinical development as quick as possible,” Freyn said, “and went from conception to a pivotal [non-human primate] study in half a year.”

Moderna’s vaccine candidate, mRNA-1769, contains mRNA molecules that code for four proteins found on the surface of the monkeypox virus (the virus itself is called monkeypox, while the disease the virus causes is mpox). Recipients' bodies then turn the mRNA into viral proteins, which the immune system can learn to recognize and fight against.

The four chosen proteins are vital for the virus to replicate and are highly conserved across monkeypox’s relatives, the orthopox viruses. Freyn said the team has tested the vaccine in the lab against other orthopox viruses, like camelpox, rabbitpox and multiple mpox strains, and found it neutralizes them. “We think that we can protect against a broad range of orthopox viruses,” he said.

Freyn and colleagues put mRNA-1769 to the test in cynomolgus macaques, monkeys commonly used in animal studies. They randomized 18 macaques into three groups, with six monkeys each receiving Jynneos, mRNA-1769 or a saline solution control. After vaccination, the team injected the simians with a variant of mpox known to be lethal.

Five of the control macaques succumbed to the illness, while all of the vaccinated animals survived. Monkeys that received the mRNA vaccine showed the fewest lesions, a hallmark of mpox, with an average peak lesion count of 54. The Jynneos group had an average peak of 607, with all these macaques falling into the WHO’s classifications for severe disease (more than 100 lesion) or grave disease (more than 250 lesions). None of the mRNA vaccine recipients developed severe or grave mpox.

“We were very excited to see the mRNA vaccine performing quite well, especially in reducing the duration of disease and reducing the amount of lesions,” Freyn said.

But for Freyn, the most striking result is that the mRNA vaccine group had lower levels of monkeypox virus in their blood and throats compared to the Jynneos group. “I was definitely surprised by how well we were able to control virus in respiratory tissue,” Freyn said. “This is a nice additional piece of data that we can drive antibodies to the respiratory tract and potentially prevent transmission, but that will require additional study.”

“This reduced viral load could result in a lower risk of transmission, especially in at-risk populations,” Nachega said. “By controlling viral shedding, the vaccine could be a critical tool in limiting the spread of mpox.”

The team also found that exposure to mRNA-1769 led the macaques to produce antibodies that bound to the viral proteins stronger than antibodies produced by Jynneos. This may be because of the nature of the mRNA platform, Freyn said. 

With the mRNA vaccine, the body is essentially told to focus solely on four key viral proteins; in contrast, Jynneos uses a weakened form of the monkeypox virus in its vaccine (a common technique), which means the immune system has to do more to decipher the right proteins to learn and target.

With its mettle tested in macaques, mRNA-1769 is now being put through a phase 1/2 clinical trial of 351 adults in the United Kingdom, with results set to read out by mid-2025. 

An mRNA vaccine from Germany company BioNTech, BNT166, is also in clinical trials after previously proving it can protect mice and macaques from mpox. That company's phase 1/2 trial, enrolling 64 people, is also set to wrap up by the middle of next year. At this point, there’s no way to directly compare Moderna’s vaccine to BNT166 or any other mRNA vaccines, Freyn said.

https://www.fiercebiotech.com/research/modernas-mpox-vaccine-prevents-severe-symptoms-and-reduces-viral-load-compared-bavarian

WSJ: Trump to Adopt Musk Plan For Gov Efficiency Panel for "Complete Financial Audit" On Fed Gov

 Former President Trump plans to adopt Elon Musk's proposed new commission, the Department of Government Efficiency abbreviated as 'DOGE.' According to The Wall Street Journal, Trump could unveil the new government efficiency commission as early as today. 

Trump plans to unveil the government efficiency commission before he delivers a speech at the Economic Club of New York. He will tell reporters that the commission would conduct "a complete financial and performance audit of the entire federal government" and make "recommendations for drastic reform." 

The commission's primary goal is to identify ways to eliminate fraud and improper payments, according to portions of the speech viewed by journos at WSJ. 

Trump's upcoming speech and proposed commission to address the failures of Biden-Harris' Bidenomics, which sparked an inflation storm and financially crushed mid—and low-tier consumers, also aims at deregulation. Trump has actively championed deregulation to make the economy great again.

Musk endorsed Trump on X shortly after the failed assassination attempt on July 13. He pledged millions of dollars to a super PAC supporting causes on the right. 

Speaking with Reuters last week, the former president said he would offer Musk a position if he were seriously interested. 

" He's a very smart guy. I certainly would—if he would do it, I certainly would," the former president said. "He's a brilliant guy."

Musk and Trump first publicly discussed a government efficiency commission during a two-hour conversation on X on August 13. The conversation has received 60.4 million views so far. 

Musk shared an AI picture last month of himself standing at a platform that read "Department of Government Efficiency" (DOGE) and wrote on X, "I am willing to serve."

Earlier this week, Musk reiterated, "I can't wait. There is a lot of waste and needless regulation in government that needs to go." 

On X this morning, Musk responded to one user's post about WSJ's story. He said, "I look forward to serving America if the opportunity arises. No pay, no title, no recognition is needed."

Trump also plans to say, "This election will decide whether we reward Kamala Harris with re-election and four more years of economic calamity—or whether we change direction." 

Let's not forget that the federal government loses between $233 billion and $521 billion to fraud annually, or about $4,000 per American household, as per The Hill

https://www.zerohedge.com/political/trump-announce-elon-musks-proposal-government-efficiency-commission

Voyager Enters into License for Next-Generation Capsid

 

Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE: NVS) has agreed to license a novel capsid generated from Voyager’s TRACER™ capsid discovery platform for use in a gene therapy program against an undisclosed rare neurologic disease target. This capsid license is being granted pursuant to the agreement between Voyager and Novartis originally announced in March 2022.